PL385586A1 - Nowe analogi insuliny o przedłużonym działaniu - Google Patents
Nowe analogi insuliny o przedłużonym działaniuInfo
- Publication number
- PL385586A1 PL385586A1 PL385586A PL38558608A PL385586A1 PL 385586 A1 PL385586 A1 PL 385586A1 PL 385586 A PL385586 A PL 385586A PL 38558608 A PL38558608 A PL 38558608A PL 385586 A1 PL385586 A1 PL 385586A1
- Authority
- PL
- Poland
- Prior art keywords
- insulin analogues
- release insulin
- new slow
- new
- slow
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Ujawniono nowe biosyntetyczne analogi rekombinowanej insuliny ludzkiej o przedłużonym działaniu terapeutycznym, które mogą znaleźć zastosowanie w profilaktyce i terapii cukrzycy.
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL385586A PL219335B1 (pl) | 2008-07-04 | 2008-07-04 | Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna |
CN2009801261044A CN102083855A (zh) | 2008-07-04 | 2009-07-04 | 活性延长的新胰岛素类似物 |
PL11003008T PL2371853T3 (pl) | 2008-07-04 | 2009-07-04 | Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, kompozycja farmaceutyczna, zastosowanie pochodnej insuliny lub jej farmaceutycznie dopuszczalnej soli oraz sposób leczenia |
PCT/PL2009/050010 WO2010002283A2 (en) | 2008-07-04 | 2009-07-04 | New insulin analogues of prolonged activity |
EA201170149A EA023559B1 (ru) | 2008-07-04 | 2009-07-04 | Аналоги инсулина человека с пролонгированной терапевтической активностью, стабильные в кислой среде |
EP09773816A EP2321344A2 (en) | 2008-07-04 | 2009-07-04 | New insulin analogues of prolonged activity |
EP11003008.7A EP2371853B1 (en) | 2008-07-04 | 2009-07-04 | Insulin derivatives or its pharmaceutically acceptable salt, pharmaceutical composition, use of insulin derivative or its pharmaceutically acceptable salt and method of treatment |
JP2011516197A JP2011526886A (ja) | 2008-07-04 | 2009-07-04 | 持効型活性を有する新規インスリン類似体 |
US13/002,520 US8618048B2 (en) | 2008-07-04 | 2009-07-04 | Insulin analogues of prolonged activity |
CA2729938A CA2729938C (en) | 2008-07-04 | 2009-07-04 | New insulin analogues of prolonged activity |
US14/090,496 US20140121353A1 (en) | 2008-07-04 | 2013-11-26 | Insulin analogues of prolonged activity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL385586A PL219335B1 (pl) | 2008-07-04 | 2008-07-04 | Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna |
Publications (2)
Publication Number | Publication Date |
---|---|
PL385586A1 true PL385586A1 (pl) | 2010-01-18 |
PL219335B1 PL219335B1 (pl) | 2015-04-30 |
Family
ID=41130257
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL385586A PL219335B1 (pl) | 2008-07-04 | 2008-07-04 | Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna |
PL11003008T PL2371853T3 (pl) | 2008-07-04 | 2009-07-04 | Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, kompozycja farmaceutyczna, zastosowanie pochodnej insuliny lub jej farmaceutycznie dopuszczalnej soli oraz sposób leczenia |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL11003008T PL2371853T3 (pl) | 2008-07-04 | 2009-07-04 | Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, kompozycja farmaceutyczna, zastosowanie pochodnej insuliny lub jej farmaceutycznie dopuszczalnej soli oraz sposób leczenia |
Country Status (8)
Country | Link |
---|---|
US (2) | US8618048B2 (pl) |
EP (2) | EP2321344A2 (pl) |
JP (1) | JP2011526886A (pl) |
CN (1) | CN102083855A (pl) |
CA (1) | CA2729938C (pl) |
EA (1) | EA023559B1 (pl) |
PL (2) | PL219335B1 (pl) |
WO (1) | WO2010002283A2 (pl) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10100098B2 (en) | 2006-12-13 | 2018-10-16 | Stelis Biopharma Private Limited | Insulin production methods and proinsulin constructs |
EP2370462B1 (en) | 2008-12-15 | 2014-07-16 | Zealand Pharma A/S | Glucagon analogues |
JP5635529B2 (ja) | 2008-12-15 | 2014-12-03 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
BRPI0823376A2 (pt) | 2008-12-15 | 2015-06-16 | Zealand Pharma As | Análagos de glucagon |
CA2747155A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
EP2454282B1 (en) | 2009-07-13 | 2015-03-04 | Zealand Pharma A/S | Acylated glucagon analogues |
AR081975A1 (es) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
CA2802897A1 (en) | 2010-06-24 | 2011-12-29 | Zealand Pharma A/S | Glucagon analogues |
EA201390796A1 (ru) | 2011-01-20 | 2014-07-30 | Зилэнд Фарма А/С | Применение ацилированного аналога глюкагона |
WO2012115638A1 (en) * | 2011-02-23 | 2012-08-30 | Elona Biotechnologies | Glargine proinsulin compositions and methods of producing glargine insulin analogs therefrom |
EP2844669B1 (en) | 2012-05-03 | 2018-08-01 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
PL222975B1 (pl) * | 2012-05-23 | 2016-09-30 | Inst Biotechnologii I Antybiotyków | Analog insuliny lub jego farmaceutycznie dopuszczalna sól, kompozycja farmaceutyczna o przedłużonym działaniu terapeutycznym oraz zastosowanie analogu insuliny |
US9624287B2 (en) | 2012-07-17 | 2017-04-18 | Case Western Reserve University | O-linked carbohydrate-modified insulin analogues |
WO2014015078A1 (en) * | 2012-07-17 | 2014-01-23 | Michael Weiss | O-linked carbohydrate-modified insulin analogues |
EA033399B1 (ru) | 2012-07-23 | 2019-10-31 | Zealand Pharma As | Аналоги глюкагона с повышенной растворимостью и/или стабильностью и их применение |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
US20150361154A1 (en) * | 2013-01-15 | 2015-12-17 | Phasebio Pharmaceuticals, Inc. | Therapeutic agents, compositions, and methods for glycemic control |
WO2014122653A1 (en) * | 2013-02-07 | 2014-08-14 | Valin Technologies Ltd. | Process for preparing insulin |
WO2014122651A1 (en) * | 2013-02-07 | 2014-08-14 | Valin Technologies Ltd. | Process for preparing insulin |
CN103981243A (zh) * | 2013-02-07 | 2014-08-13 | 华凌科技有限公司 | 胰岛素的制备方法 |
CN103981242A (zh) * | 2013-02-07 | 2014-08-13 | 华凌科技有限公司 | 胰岛素的制备方法 |
KR102569036B1 (ko) | 2013-10-17 | 2023-08-23 | 질랜드 파마 에이/에스 | 아실화된 글루카곤 유사체 |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
WO2015067715A2 (en) | 2013-11-06 | 2015-05-14 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
EA035688B1 (ru) | 2013-11-06 | 2020-07-27 | Зилэнд Фарма А/С | Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip |
JP6898231B6 (ja) | 2014-10-29 | 2021-07-28 | ジーランド ファーマ アクティーゼルスカブ | Gipアゴニスト化合物及び方法 |
US10336802B2 (en) | 2015-04-16 | 2019-07-02 | Zealand Pharma A/S | Acylated glucagon analogue |
PL239062B1 (pl) * | 2016-01-22 | 2021-11-02 | Inst Biotechnologii I Antybiotykow | Sposób wytwarzania insuliny i jej pochodnych |
JP7286160B2 (ja) * | 2016-11-21 | 2023-06-05 | ケース ウェスタン リザーブ ユニバーシティ | 安定性が増強された速効性インスリン類似体 |
KR102666154B1 (ko) * | 2018-08-08 | 2024-05-20 | 주식회사 대웅제약 | 지속형 인슐린 아날로그 및 그 복합체 |
CN113423691A (zh) * | 2018-12-11 | 2021-09-21 | 赛诺菲 | 肽结合剂 |
EP4048686A4 (en) * | 2019-10-24 | 2024-01-03 | Univ Utah Res Found | NEW MINI INSULIN WITH EXTENDED C-TERMINAL A-CHAIN |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3327709A1 (de) | 1983-07-29 | 1985-02-07 | Hoechst Ag, 6230 Frankfurt | Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung |
US5434247A (en) * | 1986-10-10 | 1995-07-18 | Board Of Regents, The University Of Texas System | Peptides for inducing monocyte cytotoxicity in diagnostics |
US5135736A (en) * | 1988-08-15 | 1992-08-04 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
DE3837825A1 (de) * | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
DE3844211A1 (de) * | 1988-12-29 | 1990-07-05 | Hoechst Ag | Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
DK0547544T3 (da) * | 1991-12-18 | 1997-09-08 | Hoechst Ag | Fremgangsmåde til fremstilling af insulinholdige opløsninger. |
BR9306042A (pt) | 1992-02-28 | 1997-11-18 | Autoimmune Inc | Método para tratar uma doença auto-immune em um mamifero e formas de dosagens farmacêuticas oral e inalável |
DE4405179A1 (de) | 1994-02-18 | 1995-08-24 | Hoechst Ag | Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken |
DE19652713C2 (de) | 1996-12-18 | 2001-11-22 | Aventis Pharma Gmbh | Verfahren zur Reinigung von Insulin und Insulinderivaten durch Chromatographie an stark saurem Kationenaustauscher |
DE19825447A1 (de) | 1998-06-06 | 1999-12-09 | Hoechst Marion Roussel De Gmbh | Neue Insulinanaloga mit erhöhter Zinkbildung |
JP3971108B2 (ja) * | 1999-01-06 | 2007-09-05 | ジェネンテック・インコーポレーテッド | インシュリン様成長因子(igf)i突然変異体 |
US6777207B2 (en) | 1999-12-29 | 2004-08-17 | Novo Nordisk A/S | Method for making insulin precursors and insulin precursor analogues having improved fermentation yield in yeast |
US7547821B2 (en) * | 2003-06-17 | 2009-06-16 | Sembiosys Genetics Inc. | Methods for the production of insulin in plants |
PL213561B1 (pl) | 2004-01-09 | 2013-03-29 | Inst Biotechnologii I Antybiotykow | Sposób otrzymywania plazmidu, plazmid oraz zastosowania |
US7893197B2 (en) * | 2004-08-25 | 2011-02-22 | Janssen Pharmaceutica N.V. | Relaxin-3 chimeric polypeptides and their preparation and use |
EP1796708A4 (en) * | 2004-09-02 | 2009-07-08 | Cognosci Inc | IMPROVED APO-E ANALOGS AND USE METHOD THEREFOR |
PL373543A1 (pl) * | 2005-03-10 | 2006-09-18 | Instytut Biotechnologii i Antybiotyków | Kompozycja farmaceutyczna zawierająca biosyntetyczny analog insuliny ludzkiej, oraz jej zastosowanie w terapii cukrzycy |
EP2371851A3 (en) * | 2005-06-17 | 2012-08-01 | Mannkind Corporation | Epitope analogues |
DE102005051366A1 (de) * | 2005-10-25 | 2007-04-26 | Degussa Gmbh | Drug Delivery Systeme |
JP2009530243A (ja) * | 2006-03-13 | 2009-08-27 | ノボ・ノルデイスク・エー/エス | アシル化単鎖インスリン |
CN101573133B (zh) * | 2006-07-31 | 2014-08-27 | 诺沃-诺迪斯克有限公司 | Peg化延长的胰岛素 |
WO2008049711A1 (en) * | 2006-10-27 | 2008-05-02 | Novo Nordisk A/S | Peptide extended insulins |
-
2008
- 2008-07-04 PL PL385586A patent/PL219335B1/pl unknown
-
2009
- 2009-07-04 CA CA2729938A patent/CA2729938C/en not_active Expired - Fee Related
- 2009-07-04 EP EP09773816A patent/EP2321344A2/en not_active Withdrawn
- 2009-07-04 WO PCT/PL2009/050010 patent/WO2010002283A2/en active Application Filing
- 2009-07-04 EP EP11003008.7A patent/EP2371853B1/en not_active Not-in-force
- 2009-07-04 US US13/002,520 patent/US8618048B2/en not_active Expired - Fee Related
- 2009-07-04 EA EA201170149A patent/EA023559B1/ru not_active IP Right Cessation
- 2009-07-04 JP JP2011516197A patent/JP2011526886A/ja active Pending
- 2009-07-04 PL PL11003008T patent/PL2371853T3/pl unknown
- 2009-07-04 CN CN2009801261044A patent/CN102083855A/zh active Pending
-
2013
- 2013-11-26 US US14/090,496 patent/US20140121353A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20110136736A1 (en) | 2011-06-09 |
EA023559B1 (ru) | 2016-06-30 |
PL219335B1 (pl) | 2015-04-30 |
JP2011526886A (ja) | 2011-10-20 |
US20140121353A1 (en) | 2014-05-01 |
US8618048B2 (en) | 2013-12-31 |
CA2729938C (en) | 2018-11-06 |
EP2371853A2 (en) | 2011-10-05 |
WO2010002283A3 (en) | 2010-04-29 |
EP2371853A3 (en) | 2012-10-03 |
EA201170149A1 (ru) | 2011-06-30 |
PL2371853T3 (pl) | 2018-06-29 |
CN102083855A (zh) | 2011-06-01 |
EP2321344A2 (en) | 2011-05-18 |
WO2010002283A9 (en) | 2011-01-20 |
EP2371853B1 (en) | 2017-09-13 |
WO2010002283A2 (en) | 2010-01-07 |
CA2729938A1 (en) | 2010-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL385586A1 (pl) | Nowe analogi insuliny o przedłużonym działaniu | |
PH12018500767A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
EA201991014A1 (ru) | Лечение диабета | |
IL250548A0 (en) | Acetyl analogs of insulin that are resistant to protease and their use for the preparation of a drug for the treatment and prevention of diabetes | |
MX2013004406A (es) | Tratamiento de diabetes mellitus usando inyecciones de insulina administradas con intervalos variables de inyeccion. | |
IL201479A (en) | Use of tapentadol for the preparation of pain medication | |
MX2013004699A (es) | Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos. | |
GEP20146056B (en) | Acylated glucagon analogues | |
MX2008013304A (es) | Compuestos de peptido 1 tipo glucagon. | |
EA201101117A1 (ru) | Ингибиторы дпп-4 для лечения диабета у детей | |
GB2465677B (en) | Non-systemic delivery of satiogens for use in the treatment of obesity and/or diabetes | |
EA201200793A1 (ru) | Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин | |
TN2011000176A1 (en) | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug | |
MX2014015423A (es) | Analogos de peptido de exedina-4. | |
GB2491328A (en) | Immediate/delayed drug delivery | |
NZ719520A (en) | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway | |
BR112013029256A2 (pt) | "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina". | |
MX347372B (es) | Uso de metformina en combinacion con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa. | |
EP2566502A4 (en) | METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION | |
EP1997503A3 (en) | Treatment of melanoma with alpha thymosin peptides | |
UA112981C2 (uk) | Варіант людського gdnf | |
WO2010075444A3 (en) | Nasal formulations of metoclopramide | |
MX364643B (es) | USO DEL COMPUESTO FTY720: 2-amino - 2-[2-(4-octilfenil) etil] propano-1,3-diol (fingolimod) EN EL TRATAMIENTO DE PACIENTES CON DIABETES DE TIPO 2. | |
WO2008055092A3 (en) | Use of enoxaparin sodium for treating patients with acute ischemic stroke | |
EA202090141A1 (ru) | Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин |